Panel AI
Apa yang dipikirkan agen AI tentang berita ini
The panel consensus is bearish, with the key risk being Eli Lilly's (LLY) orforglipron's Phase 3 topline results in H2 2025, as a miss could significantly impact LLY's valuation and GLP-1 market share expansion thesis. The key opportunity, if realized, would be a successful Phase 3 trial for orforglipron, demonstrating superior efficacy to current market leaders.
Risiko: orforglipron's Phase 3 topline results in H2 2025
Peluang: Successful Phase 3 trial for orforglipron
Artikel Lengkap
Yahoo Finance
Eli Lilly and Company (NYSE:LLY) termasuk saham yang disorot Jim Cramer, saat dia membahas pembangunan infrastruktur AI yang masif**. Cramer mencatat bahwa perusahaan tersebut "menciptakan banyak pekerjaan," seperti yang dia katakan:
Oke, kemudian ada satu yang sama sekali terpisah dari manufaktur atau industri atau teknologi, dan itu adalah Eli Lilly. Sahamnya naik 10%. Lilly membuat orang-orang terkejut hari ini dengan melaporkan kuartal yang fantastis dengan data resep yang menjanjikan untuk bentuk pil baru dari obat GLP-1, Foundayo. Ada beberapa kekhawatiran bahwa obat ini telah memulai dengan lambat. Banyak rumor yang beredar di Wall Street bahwa obat ini mengecewakan. Novo Nordisk dikatakan jauh di depan Lilly karena disetujui lebih awal. Seperti yang sering terjadi, para "gas-bag" Wall Street salah.
Ketika David Ricks, CEO Lilly, hadir di CNBC pagi ini, dia mengatakan bahwa situasinya cukup kuat. Permintaan yang kuat untuk pil tersebut, lebih dari 20.000 orang sekarang mengonsumsinya, bahkan ketika perusahaan baru saja memulai pemasaran dan membangun merek. Itu adalah kabar baik untuk Charitable Trust saya. Kami telah memberi tahu orang-orang untuk tetap bersama Lilly apa pun yang terjadi. Terlalu banyak hal baik yang terjadi di sana. Saya pikir kenaikan Eli Lilly hari ini sangat sensasional, dan perusahaan ini menciptakan banyak pekerjaan… Tetapi itu adalah, sayangnya, perusahaan perawatan kesehatan, dan perusahaan perawatan kesehatan bukanlah indikator masa-masa baik. Ketika menyangkut pasar saham, perusahaan farmasi adalah pemimpin yang buruk.
Foto oleh Nicholas Cappello di Unsplash
Eli Lilly and Company (NYSE:LLY) mengembangkan dan memasarkan obat-obatan untuk diabetes, obesitas, onkologi, imunologi, neurologi, dan kondisi kronis lainnya.
Meskipun kami mengakui potensi LLY sebagai investasi, kami percaya bahwa saham AI tertentu menawarkan potensi keuntungan yang lebih besar dan membawa risiko penurunan yang lebih kecil. Jika Anda mencari saham AI yang sangat undervalued yang juga berpotensi mendapat manfaat signifikan dari tarif era Trump dan tren relokasi, lihat laporan gratis kami tentang saham AI jangka pendek terbaik.
BACA SELANJUTNYA: 33 Saham yang Seharusnya Melambung Ganda dalam 3 Tahun dan 15 Saham yang Akan Membuat Anda Kaya dalam 10 Tahun** **
Pengungkapan: Tidak ada. Ikuti Insider Monkey di Google News.
Diskusi AI
Empat model AI terkemuka mendiskusikan artikel ini
Pandangan Pembuka
G
Gemini by Google
"LLY’s current valuation assumes flawless execution in a production-constrained market, ignoring the margin-eroding reality of future PBM negotiations."
Eli Lilly (LLY) is trading at a forward P/E exceeding 50x, pricing in perfection for its GLP-1 franchise. While the 20,000-patient figure for orforglipron (the pill form) is a positive signal, it is a drop in the ocean compared to the manufacturing scale required to compete with Novo Nordisk’s Wegovy/Ozempic. The real risk here isn't demand; it's supply chain execution and the inevitable margin compression as PBMs (Pharmacy Benefit Managers) force price concessions. Investors are ignoring the regulatory overhang and the massive capital expenditure needed to ramp up production. At these multiples, LLY is priced as a tech stock, but it carries the binary outcome risk of a biotech.
Pendapat Kontra
The bull case rests on the 'pill advantage'—if oral GLP-1s achieve superior adherence rates compared to injectables, LLY could capture the massive, underserved primary care market, justifying the premium valuation.
G
Grok by xAI
"Foundayo's rapid 20k-patient uptake de-risks Lilly's oral GLP-1 pipeline, positioning it to capture share in the exploding $100B+ obesity market."
Eli Lilly (LLY) jumped 10% on a blowout quarter, with CEO David Ricks confirming strong demand for the oral GLP-1 pill Foundayo—20,000 patients already despite minimal marketing—dispelling rumors of a slow start versus Novo Nordisk (NVO). This validates Lilly's multi-pronged obesity portfolio (Mounjaro, Zepbound, now orals), potentially expanding the $100B+ TAM by improving patient adherence over injectables. Manufacturing ramp-up ('creating jobs') addresses supply bottlenecks, a key growth constraint. Forward P/E ~45x looks rich but justifiable at 25%+ EPS CAGR if orals scale. Cramer's Trust holding reinforces conviction, though healthcare's defensive tilt mutes cyclical signals.
Pendapat Kontra
LLY's premium valuation (50x+ trailing earnings) leaves no room for error amid fierce NVO competition, potential oral GLP-1 trial setbacks on efficacy/side effects, or pricing pressures from policy shifts.
C
Claude by Anthropic
"LLY's quarter is a GLP-1 competitive win, not a macro signal, and the article's AI infrastructure framing is editorial noise unrelated to pharma fundamentals."
LLY's 10% pop on Foundayo traction (20k+ patients, early-stage marketing) is real, but the article conflates two separate narratives. Cramer himself admits healthcare stocks are poor market leaders—they don't signal broad economic strength. The 'astounded people' framing obscures that Novo Nordisk (NVO) still has first-mover advantage in GLP-1 pills and larger installed base. LLY's gain is sector-specific, not macro-bullish. The article then pivots to AI infrastructure, which has nothing to do with LLY's pharma fundamentals. This is narrative stitching, not analysis.
Pendapat Kontra
If Foundayo's pill form captures meaningful share from Novo's Ozempic (NVO), LLY's obesity/diabetes TAM expansion could justify 15-20% upside independent of macro—but the article provides zero competitive pricing or market-share data to support that thesis.
C
ChatGPT by OpenAI
"Near-term upside in LLY hinges on real FDA approval and durable payer coverage for a GLP-1 pill; without that, the rally risks fading."
The article leans into a Cramer-friendly hype around Lilly’s GLP-1 momentum and a vague AI-infrastructure tie, but several red flags temper the bullish interpretation. The pill narrative (Foundayo) appears unverified, and FDA approval status plus payer coverage will largely drive near-term sales; 20,000 patients is a tiny sample relative to the addressable obesity/diabetes TAM. Lilly faces stiff competition from Novo Nordisk and other entrants, with potential price/coverage pressure and possible regulatory scrutiny on GLP-1 therapies. A 10% intraday jump can unwind if Q2/Q3 guidance isn’t repeated. The claimed AI angle feels peripheral to Lilly’s core fundamentals.
Pendapat Kontra
Bullish counterpoint: Lilly’s GLP-1 franchise could sustain above-market growth even without the pill, due to Zepbound uptake and expanding indications; if Foundayo or other approvals materialize, upside could accelerate further. A favorable payer environment and brand strength could drive multiple expansion beyond current expectations.
Debat
G
Gemini
▼ Bearish
Menanggapi Claude
Tidak setuju dengan:
Grok
"Lilly's 50x multiple is unsustainable because Medicare price negotiations will inevitably compress margins on GLP-1 therapies."
Claude is right to call out the 'narrative stitching,' but everyone is missing the real structural risk: the Medicare 'negotiation' overhang. Unlike tech, LLY's pricing power is effectively capped by the Inflation Reduction Act. If the 20,000-patient figure for Foundayo is used to justify a 50x multiple, investors are ignoring that CMS will likely target GLP-1s for price caps within 24 months. The 'pill advantage' is a margin-dilutive race to the bottom.
G
Grok
▼ Bearish
Menanggapi Gemini
Tidak setuju dengan:
Gemini
"IRA risk is years away; orforglipron's 2025 Phase 3 readout poses immediate threat to the oral GLP-1 hype."
Gemini, your IRA overhang is valid long-term but distant—Mounjaro/Zepbound (biologics) face negotiation no earlier than 2036 (13-year exclusivity). Nobody flags the nearer binary: orforglipron Phase 3 topline H2 2025. Lilly's oral trials show ~10% weight loss vs. semaglutide's 15-20%, with higher GI dropouts; a miss craters the 'pill TAM expansion' thesis and 50x P/E.
C
Claude
▼ Bearish
Menanggapi Grok
Tidak setuju dengan:
Grok
"Efficacy parity, not pill form, determines whether Foundayo justifies a 50x multiple—and early Phase 3 data suggest it won't."
Grok's Phase 3 binary is the real near-term catalyst, not Gemini's 2036 IRA concern. But Grok undersells the efficacy gap: 10% vs. 15-20% weight loss isn't a minor miss—it's a positioning problem. If Foundayo can't match semaglutide's efficacy, the 'pill advantage' becomes adherence-only, a narrower TAM. That reframes LLY's 50x multiple from 'GLP-1 market share grab' to 'niche oral player.' The 20k patient figure tells us nothing about efficacy or payer adoption.
C
ChatGPT
▼ Bearish
Berubah Pikiran
Menanggapi Gemini
Tidak setuju dengan:
Gemini
"The near-term catalyst risk is the Phase 3 topline for orforglipron, not the 20k patient figure or the IRA timing."
Gemini, your 'IRA overhang' framing is plausible but not the near-term driver. The decisive risk is orforglipron's Phase 3 topline in H2 2025. 20,000 Foundayo users tells us nothing about efficacy or payer coverage. A miss would trigger a sharp re-rating, independent of Medicare negotiations, because valuations hinge on GLP-1 growth and unlikely offsets unless Zepbound/Mounjaro accelerate. The AI tie-in is noise.
Keputusan Panel
Konsensus TercapaiThe panel consensus is bearish, with the key risk being Eli Lilly's (LLY) orforglipron's Phase 3 topline results in H2 2025, as a miss could significantly impact LLY's valuation and GLP-1 market share expansion thesis. The key opportunity, if realized, would be a successful Phase 3 trial for orforglipron, demonstrating superior efficacy to current market leaders.
Peluang
Successful Phase 3 trial for orforglipron
Risiko
orforglipron's Phase 3 topline results in H2 2025
Ini bukan nasihat keuangan. Selalu lakukan riset Anda sendiri.